Posaconazole

Generic Name: Posaconazole

Brand Names: Noxafil, Posanol, Posaconazole Accord, Posaconazole AHCL

Drug Type: Small Molecule

Chemical Formula: C_₃₇H_₄₂F_₂N_₈O_₄

CAS Number: 171228-49-2

Unique Ingredient Identifier: 6TK1G07BHZ

Background: Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

Indication: For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with...

Associated Conditions: Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Invasive bronchopulmonary aspergillosis, Mucormycosis, Oropharyngeal Candidiasis, Prophylaxis of Aspergillus infection, Pulmonary cryptococcosis infection

Associated Therapies: -

Clinical Trials

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
Myelogenous Leukemia
Treatment Naive AML

Interventions: Drug: ABT-199
Drug: Posaconazole
Drug: Azacitidine
Drug: Decitabine

First Posted Date: 2014-07-30

Last Posted Date: 2023-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 212

Registration Number: NCT02203773

Locations: 🇺🇸
Johns Hopkins University /ID# 129699, Baltimore, Maryland, United States
🇺🇸
Northwestern University Feinberg School of Medicine /ID# 128741, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute /ID# 127857, Boston, Massachusetts, United States

and more 20 locations

Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)

Phase 3

Completed

Conditions: Aspergillosis

Interventions: Drug: Voriconazole
Drug: Posaconazole

First Posted Date: 2014-07-02

Last Posted Date: 2021-01-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 116

Registration Number: NCT02180165

Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection.

Phase 4

Withdrawn

Conditions: Clinical Infection

Interventions: Drug: Posaconazole

First Posted Date: 2013-12-24

Last Posted Date: 2014-12-12

Lead Sponsor: Taichung Veterans General Hospital

Registration Number: NCT02020213

A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Alectinib
Drug: Posaconazole

First Posted Date: 2013-11-14

Last Posted Date: 2016-10-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT01984229

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: RO5503781
Drug: posaconazole

First Posted Date: 2013-07-17

Last Posted Date: 2015-08-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 61

Registration Number: NCT01901172

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Phase 3

Completed

Conditions: Fungal Infections
Invasive Pulmonary Aspergillosis

Interventions: Drug: Posaconazole
Drug: Voriconazole
Drug: Placebo

First Posted Date: 2013-02-01

Last Posted Date: 2024-01-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 585

Registration Number: NCT01782131

A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)

Phase 4

Terminated

Conditions: Fungal Infection

Interventions: Drug: Posaconazole
Drug: Calogen®

First Posted Date: 2012-08-17

Last Posted Date: 2018-10-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 26

Registration Number: NCT01667107

A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)

Phase 2

Completed

Conditions: Chagas Disease

Interventions: Drug: Placebo for posaconazole
Drug: Posaconazole
Drug: Benznidazole

First Posted Date: 2011-06-21

Last Posted Date: 2018-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT01377480

Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

Phase 4

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: posaconazole
Drug: micafungin

First Posted Date: 2010-09-13

Last Posted Date: 2018-05-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 113

Registration Number: NCT01200355

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole

Phase 2

Completed

Conditions: Chagas Disease

Interventions: Drug: Posaconazole
Drug: Benznidazole

First Posted Date: 2010-07-15

Last Posted Date: 2013-09-10

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 78

Registration Number: NCT01162967

Locations: 🇪🇸
International Health Unit Drassanes, Barcelona, Spain
🇪🇸
Infectious Disease Department Vall d'Hebron Hospital, Barcelona, Spain
🇪🇸
International Health Unit Metropolitana Nord, Santa Coloma, Barcelona, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy